Adjuvant palbociclib in HR+/HER2-early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial

被引：1
|
作者：
Gnant, Michael
Dueck, Amylou C.
Frantal, Sophie
Martin, Miguel
Burstein, Hal
Greil, Richard
Fox, Peter
Wolff, Antonio C.
Chan, Arlene
Winer, Eric
Singer, Christian
Miller, Kathy
Colleoni, Marco
Naughton, Michelle
Rubovszky, Gabor
Bliss, Judith
Mayer, Ingrid A.
Steger, Guenther G.
Nowecki, Zbigniew
Hahn, Olwen
Wolmark, Norman
Rugo, Hope
Pfeiler, Georg
Fohler, Hannes
Metzger, Otto
Schurmans, Celine
Theall, Kathy P.
Lu, Dongrui R.
Tenner, Kathleen
Fesl, Christian
DeMichele, Angela
Mayer, Erica L.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-GS1-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS1-07
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Real-world treatment of HER2+and HR+/HER2-early breast cancer in county areas of China
    Ji, Y.
    Wang, J.
    Dai, G.
    Zhou, F.
    Meng, Q.
    Wu, Q.
    Qu, H.
    Liu, H.
    Liu, M.
    Tian, Y.
    Tan, X.
    He, W.
    Qin, Z.
    Tang, H.
    Luo, G.
    Liu, Y.
    Ren, Y.
    Luo, J.
    Wang, M.
    Lu, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1474 - S1474
  • [32] Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2-Metastatic Breast Cancer
    Jeselsohn, Rinath
    Fu, Jingxin
    Ren, Yue
    Mahtani, Reshma
    Ma, Cynthia
    DeMichele, Angela
    Cristofanilli, Massimo
    Meisel, Jane
    Miller, Kathy
    Abdou, Yara
    Riley, Elizabeth
    Qamar, Rubina
    Sharma, Priyanka
    Reid, Sonya
    Ko, Naomi
    Liu, Yuan
    Burstein, Harold
    DeMeo, Michelle
    Tolaney, Sara
    Mayer, Erica
    CANCER RESEARCH, 2024, 84 (09)
  • [33] Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial
    Huang, Liang
    Pang, Da
    Yang, Hongjian
    Li, Wei
    Wang, Shusen
    Cui, Shude
    Liao, Ning
    Wang, Yongsheng
    Wang, Chuan
    Chang, Yuan-Ching
    Wang, Hwei-Chung
    Kang, Seok Yun
    Seo, Jae Hong
    Shen, Kunwei
    Laohawiriyakamol, Suphawat
    Jiang, Zefei
    Wang, Haiyan
    Lamour, Francois
    Song, Grace
    Curran, Michelle
    Duan, Chunzhe
    Lysbet de Haas, Sanne
    Restuccia, Eleonora
    Shao, Zhimin
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [34] Efficacy and safety analysis of Chinese patients in monarchE: Abemaciclib combined with adjuvant endocrine therapy for high risk HR+, HER2-early breast cancer.
    Shao Zhimin
    Zhang, Qingyuan
    Song, Chuan-gui
    Ouyang, Quchang
    Liu, Zhenzhen
    Liu, Qiang
    Feng, Jifeng
    Chiu, Joanne Wing Yan
    Tseng, Ling-Ming
    Qian, Chenxi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Multi-country study of the use of genomic assays in HR+, HER2-early breast cancer and characteristics of patients tested
    Brown, Jacqueline
    Williams, Rhys
    Rider, Alex
    Wild, Rosie
    Method, Michael
    CANCER RESEARCH, 2021, 81 (04)
  • [36] Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2-Early Breast Cancer
    Klocker, Eva Valentina
    Egle, Daniel
    Bartsch, Rupert
    Rinnerthaler, Gabriel
    Gnant, Michael
    DRUGS, 2025, 85 (02) : 149 - 169
  • [37] Clinical outcomes in patients (pts) with HR+/HER2-early breast cancer (EBC) by prior systemic treatment (tx): A subgroup analysis of the NATALEE trial
    McAndrew, N. P.
    Chia, S.
    Puglisi, F.
    Bardia, A.
    Izarzugaza Peron, Y.
    Schem, C.
    Xu, B.
    Le Du, F.
    Sharma, P.
    Afenjar, K.
    Akdere, M.
    Gonzalez, J. P. Zarate
    Chattar, Y.
    Fasching, P. A.
    ANNALS OF ONCOLOGY, 2024, 35 : S315 - S316
  • [38] Oncologists' agreement on adjuvant therapy recommendations and the need of 21-gene recurrence score assay in HR+/HER2-early breast cancer
    Castro-Henriques, M.
    Casadevall Aguilar, D.
    Monzonis, X.
    Martinez-Garcia, M.
    Martos, T.
    Corbera, A.
    Trias Bes, I. Tusquets
    Albanell, J.
    Servitja, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S317 - S317
  • [39] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
  • [40] A Multicountry Discrete Choice Experiment (DCE) to Understand Patients' Preferences for HR+/HER2-Early Breast Cancer (EBC) Treatments
    Harmer, V.
    Ammendolea, C.
    Ryan, M.
    Boyle, F.
    Werutsky, G.
    El Mouzain, D.
    Marshall, D.
    Thomas, C.
    Heidenreich, S.
    Lu, H.
    Payan, J. C. Mora
    Aubel, D.
    Danyliv, A.
    Pathak, P.
    Harbeck, N.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 47 - 47
12345